PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, published by PERGAMON-ELSEVIER SCIENCE LTD, is a leading peer-reviewed journal that serves the interdisciplinary field of neuropsychopharmacology and biological psychiatry. With an impressive impact factor in the first quartile of both Biological Psychiatry and Pharmacology categories, this journal provides a critical platform for the dissemination of cutting-edge research and innovative therapeutic approaches. Covering a broad range of topics from the molecular mechanisms underlying psychiatric disorders to advanced pharmacological interventions, it aims to foster scientific dialogue among researchers, clinicians, and students alike. The journal has been at the forefront of scientific inquiry since its inception in 1982 and continues to evolve, adapting to the ever-changing landscape of neuroscience and mental health research. With its focus on high-quality articles and a commitment to advancing the understanding of neuropsychopharmacology, this journal is essential for anyone interested in the complexities of brain function and mental health.

JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, published by MARY ANN LIEBERT, INC, stands as a premier academic journal dedicated to advancing the field of pediatric psychopharmacology. With a rich history of publication spanning from 1990 to 2024, this journal presents cutting-edge research that informs clinical practices and policy decisions impacting the mental health of children and adolescents. Ranked in the Q2 category for both Pediatrics, Perinatology and Child Health and Pharmacology (medical) as of 2023, it reflects its critical contribution to these fields, along with a respectable Q3 status in Psychiatry and Mental Health. Researchers and practitioners benefit from the journal's rigorous peer-reviewed articles, which delve into the efficacy, safety, and ethical implications of pharmacological treatments tailored for young populations. Although the journal does not currently offer Open Access, it remains a vital resource for anyone engaged in child and adolescent health research and treatment strategies. Its commitment to fostering dialogue and innovation in psychopharmacology ensures its pivotal role in shaping future standards and practices in this essential area of medical science.

Neuropsychiatric Disease and Treatment, published by DOVE MEDICAL PRESS LTD, is a prominent open access journal dedicated to advancing the field of neuropsychiatry. Since its inception in 2009, this journal has provided a platform for the dissemination of high-quality research on innovative therapies and treatments for neuropsychiatric disorders. With an impressive Q2 ranking in Psychiatry and Mental Health and a Q3 ranking in Biological Psychiatry as of 2023, it holds a reputable position within the scholarly community, reflecting its commitment to impactful research. The journal's open access model ensures widespread accessibility, fostering collaboration and dialogue among researchers, clinicians, and students worldwide. The journal accepts a variety of article types, including original research, reviews, and case studies, encompassing a range of topics from pathophysiology to therapeutic advancements. With its base in New Zealand and a Scopus rank placing it within the 69th percentile of Psychiatry and Mental Health, Neuropsychiatric Disease and Treatment is an essential resource for those dedicated to understanding and treating the complexities of neuropsychiatric conditions.

DEPRESSION AND ANXIETY is a leading academic journal published by WILEY, dedicated to presenting cutting-edge research in the fields of clinical psychology, psychiatry, and mental health. With an impressive impact factor underscoring its prominence—ranked in the top quartile (Q1) for both clinical psychology and psychiatry, and occupying the 7th and 20th ranks in Scopus respectively—this journal serves as a pivotal resource for researchers, professionals, and students alike. Since its inception in 1996 and continuing through 2024, DEPRESSION AND ANXIETY has been at the forefront of disseminating findings that significantly impact our understanding of mental health issues. The journal's rigorous peer-review process ensures the highest quality of published works, making it an essential platform for scholars aiming to advance knowledge and contribute meaningfully to the mental health discourse.

JOURNAL OF PSYCHIATRY & NEUROSCIENCE, published by the CMA-Canadian Medical Association, serves as a pivotal platform for disseminating cutting-edge research in the fields of psychiatry and neuroscience. This esteemed journal, indexed with the ISSN 1180-4882 and E-ISSN 1488-2434, focuses on advancing our understanding of mental health through meticulous peer-reviewed articles, reviews, and clinical studies. With an impressive impact within the research community, it has achieved notable rankings, including Q1 in both Medicine (miscellaneous) and Psychiatry and Mental Health, as well as Q2 in Biological Psychiatry as of 2023. The journal fosters critical dialogue among scholars and practitioners by offering insights into the complexities of brain function and mental disorders, making it a fundamental resource for healthcare professionals, researchers, and students alike. Although it operates under a subscription model, its rich content continues to inform and influence the advancement of mental health science, affirming its role in bridging the gap between research and clinical practice.

Current Psychiatry Research and Reviews is an innovative open access journal dedicated to the dynamic field of psychiatry and mental health. Published by Bentham Science Publishers Ltd, this journal provides a platform for researchers and practitioners to disseminate pivotal findings, reviews, and advancements in psychiatric research. While the journal currently holds a Q4 status in the Psychiatry and Mental Health category, it seeks to elevate standards with interdisciplinary contributions aimed at improving patient outcomes and treatment methodologies. With a publication window spanning from 2019 to 2024, the journal aims to enhance global discussions in mental health sciences, encouraging submissions that explore evidence-based practices, innovative therapeutic techniques, and the epidemiology of mental health disorders. The journal's address in the Netherlands positions it strategically within Europe’s vibrant research community, making it an essential resource for researchers, professionals, and students alike who are invested in the evolution of psychiatric science.

Welcome to the Journal of Behavior Therapy and Experimental Psychiatry, a distinguished publication in the field of psychological research, recognized for its commitment to advancing knowledge in behavior therapy and experimental psychiatry. Published by Pergamon-Elsevier Science Ltd in the United Kingdom, this journal plays a crucial role in disseminating innovative findings and theoretical advancements since its inception in 1970. With an impressive array of impact factors, this journal proudly holds a Q1 ranking in Arts and Humanities (miscellaneous) and Q2 rankings across Clinical Psychology, Experimental and Cognitive Psychology, and Psychiatry and Mental Health categories in 2023. The journal provides a platform for both established researchers and emerging scholars to share insights that enhance practice and inform policy in mental health. Although not an Open Access journal, it ensures broad accessibility to its content through institutional subscriptions and affiliations. By focusing on high-quality, rigorous research, the Journal of Behavior Therapy and Experimental Psychiatry continues to shape the understanding of behavioral interventions and their psychological implications, making it an indispensable resource for professionals and students alike.

NEUROPSYCHOPHARMACOLOGY is a prestigious academic journal dedicated to advancing our understanding of the intricate relationship between psychiatric disorders and pharmacological treatments. Published by SpringerNature in the United Kingdom, this leading journal has been a cornerstone in the field since its inception in 1987, with a converged publication timeline extending to 2024. With a remarkable impact factor and illustrious rankings—being positioned 19th in Psychiatry and Mental Health and 16th in Pharmacology—NEUROPSYCHOPHARMACOLOGY is recognized for its rigorous peer-reviewed research that informs clinical practice and enhances therapeutic interventions. The journal is classified in Q1 quartile categories for both Pharmacology and Psychiatry and Mental Health, highlighting its commitment to excellence. Researchers, professionals, and students are encouraged to contribute to this vital dialogue, as the journal does not currently offer open access, emphasizing the importance of curated, high-quality content. By publishing innovative studies and reviews, NEUROPSYCHOPHARMACOLOGY plays a crucial role in shaping the future of mental health treatments and understanding neurobiological mechanisms, making it an indispensable resource for those at the forefront of psychiatric research.

Noropsikiyatri Arsivi-Archives of Neuropsychiatry is a prominent scholarly journal dedicated to advancing knowledge in the fields of neuropsychiatry and mental health. Published by the Turkish Neuropsychiatry Association, this journal aims to disseminate high-quality research that contributes to a deeper understanding of psychiatric disorders, innovative treatment modalities, and interdisciplinary approaches in neuroscience. Based in Turkey, the journal has been in circulation since its inception, with a rich history reflecting its commitment to addressing contemporary issues in mental health care. It is currently indexed under Scopus, with notable rankings in both Psychiatry and Mental Health (Rank #378/567, 33rd Percentile) and General Neuroscience (Rank #97/113, 14th Percentile), highlighting its increasing relevance and impact in the academia. Although it is not currently an open access journal, its contributions remain vital for researchers, professionals, and students who wish to stay abreast of the latest developments and research in neuropsychiatry.

Annals of Indian Psychiatry is a premier journal dedicated to the field of mental health and psychiatry, published by Wolters Kluwer Medknow Publications. As an Open Access journal since 2017, it provides a platform for disseminating high-quality research articles, clinical studies, and reviews that address the diverse aspects of psychiatric disorders, treatment methodologies, and mental health policy in India and beyond. The journal aims to bridge gaps in the existing literature, support practitioners with evidence-based insights, and foster dialog among researchers in the psychiatric community. With an emphasis on innovative approaches and culturally relevant practices, the Annals of Indian Psychiatry serves as a vital resource for psychiatrists, psychologists, social workers, and students engaged in clinical practice and academic research. Its commitment to improving mental health outcomes in diverse populations makes it a significant contributor to the global discourse on psychiatric health.